Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

ARCTArcturus Therapeutics Holdings Inc.

Nasdaq · CIK 0001768224
Filer categoryAccelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts201

Identity from submissions API

NameArcturus Therapeutics Holdings Inc.
CIK0001768224
TickersARCT
ExchangesNasdaq
Entity typeoperating
CategoryAccelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN000000000
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone8589002660
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)1

Former names

  • None listed.
Business address
10285 SCIENCE CENTER DRIVE
SAN DIEGO
CA
CA
Mailing address
10285 SCIENCE CENTER DRIVE
SAN DIEGO
CA
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

419 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-18 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-467309 005-91046 261571695 34 8235
2026-11-16 8-K e665891_8k-arct.htm 1.01,3.02,7.01,9.01 0001193805-26-001485 001-38942 261555690 34 211030 1 1
2026-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001140361-26-043682 005-91046 261551289 34 10318
2026-11-05 10-Q 10-Q 0001193125-26-449901 001-38942 261527649 34 7937154 1 1
2026-11-05 8-K e665874_8k-arct.htm 2.02,9.01 0001193805-26-001439 001-38942 261527185 34 264076 1 1
2026-10-29 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001214659-26-013368 005-91046 261497256 34 12195
2026-10-07 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001623632-26-001546 005-91046 261445453 34 46404
2026-09-23 8-K e665798_8k-arct.htm 7.01,9.01 0001193805-26-001277 001-38942 261401135 34 6922466 1 1
2026-08-25 8-K e665725_8k-arct.htm 7.01,9.01 0001193805-26-001130 001-38942 261312288 34 589469 1 1
2026-08-06 10-Q 10-Q 0001193125-26-338090 001-38942 261249422 34 8965351 1 1
2026-08-06 8-K e665679_8k-arct.htm 2.02,9.01 0001193805-26-001039 001-38942 261248880 34 260430 1 1
2026-07-02 8-K e665618_8k-arct.htm 1.01,7.01,9.01 0001193805-26-000910 001-38942 261147692 34 209070 1 1
2026-06-15 4 xslF345X06/e665584_4-holmes.xml 0001193805-26-000829 5615
2026-06-15 4 xslF345X06/e665583_4-farrell.xml 0001193805-26-000828 5766
2026-06-15 4 xslF345X06/e665582_4-barlow.xml 0001193805-26-000827 5566
2026-06-15 4 xslF345X06/e665581_4-markels.xml 0001193805-26-000826 5635
2026-06-15 4 xslF345X06/e66580_4-slaoui.xml 0001193805-26-000825 5624
2026-06-15 4 xslF345X06/e665579_4-marquet.xml 0001193805-26-000824 5600
2026-06-15 4 xslF345X06/e665578_4-jing.xml 0001193805-26-000823 5625
2026-06-05 8-K e665552_8k-arct.htm 5.07 0001193805-26-000770 001-38942 261070321 34 202174 1 1
2026-05-07 4 xslF345X06/e665445_4-mulroy.xml 0001193805-26-000578 5884
2026-05-07 3 xslF345X06/e665444_3-mulroy.xml 0001193805-26-000577 17138
2026-05-07 10-Q 10-Q 0001193125-26-211943 001-38942 26953465 34 6322908 1 1
2026-05-07 8-K e665435_8k-arct.htm 2.02,5.02,7.01,9.01 0001193805-26-000573 001-38942 26953226 34 355379 1 1
2026-05-07 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-057041 005-91046 26952683 34 13929
2026-04-24 DEF 14A e665392_def14a-arct.htm 0001193805-26-000507 001-38942 26893540 34 749839
2026-03-26 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-000697 005-91046 26797922 34 7158
2026-03-03 10-K 10-K 0001193125-26-088391 001-38942 26715171 34 16353080 1 1
2026-03-03 8-K e665201_8k-arct.htm 2.02,9.01 0001193805-26-000214 001-38942 26713950 34 271516 1 1
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001193125-26-052923 005-91046 26636190 34 131696
2026-02-03 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-26-009576 005-91046 26590882 34 15871
2026-01-08 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001623632-26-000033 005-91046 26517494 34 46309
2025-12-30 S-3 e665045_s3-arct.htm 0001193805-25-001797 333-292486 251614162 33 1000028 1 1
2025-12-19 4 xslF345X05/e665069_4-roberts.xml 0001193805-25-001767 5697
2025-12-19 4 xslF345X05/e665060_4-chivukula.xml 0001193805-25-001766 5741
2025-12-19 4 xslF345X05/e665059_4-payne.xml 0001193805-25-001765 5725
2025-12-19 4 xslF345X05/e665058_4-kurata.xml 0001193805-25-001764 5721
2025-12-19 3 xslF345X02/e665061_3-roberts.xml 0001193805-25-001763 15837
2025-12-15 8-K e665044_8k-arct.htm 5.02,9.01 0001193805-25-001734 001-38942 251570105 34 338873 1 1
2025-11-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001193125-25-281215 005-91046 251480806 34 130326
2025-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001140361-25-041835 005-91046 251475814 34 11134
2025-11-12 10-Q 10-Q 0001193125-25-275758 001-38942 251468445 34 7121445 1 1
2025-11-12 NT 10-Q e664959_nt10q-arct.htm 0001193805-25-001558 001-38942 251468022 34 18548
2025-11-10 8-K e664953_8k-arct.htm 2.02,9.01 0001193805-25-001555 001-38942 251466245 34 271250 1 1
2025-10-27 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-25-015320 005-91046 251417384 34 12570
2025-10-22 8-K e664913_8k-arct.htm 7.01,8.01,9.01 0001193805-25-001499 001-38942 251408612 34 2341998 1 1
2025-09-26 8-K e664858_8k-arct.htm 7.01,9.01 0001193805-25-001368 001-38942 251345338 34 298514 1 1
2025-08-29 8-K e664805_8k-arct.htm 7.01,9.01 0001193805-25-001247 001-38942 251275729 34 236608 1 1
2025-08-20 4/A xslF345X05/e664797_4a-sassine.xml 0001193805-25-001215 5179
2025-08-19 4 xslF345X05/e664791_4-sassine.xml 0001193805-25-001212 5101
2025-08-11 10-Q 10-Q 0000950170-25-106560 001-38942 251202168 34 6850773 1 1
2025-08-11 8-K e664773_8k-arct.htm 2.02,9.01 0001193805-25-001175 001-38942 251201903 34 275511 1 1
2025-07-30 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-072057 005-91046 251165781 34 14103
2025-07-29 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000932471-25-000838 005-91046 251159485 34 6272
2025-06-30 8-K e664658_8k-arct.htm 7.01,9.01 0001193805-25-000946 001-38942 251092031 34 8272070 1 1
2025-06-11 4 xslF345X05/e664624_4-farrell.xml 0001193805-25-000878 5717
2025-06-11 4 xslF345X05/e664623_4-slaoui.xml 0001193805-25-000877 5576
2025-06-11 4 xslF345X05/e664622_4-marquet.xml 0001193805-25-000876 5551
2025-06-11 4 xslF345X05/e664621_4-markels.xml 0001193805-25-000875 5586
2025-06-11 4 xslF345X05/e664620_4-jing.xml 0001193805-25-000874 5576
2025-06-11 4 xslF345X05/e664619_4-barlow.xml 0001193805-25-000873 5517
2025-06-11 4 xslF345X05/e664618_4-holmes.xml 0001193805-25-000872 5566
2025-06-06 8-K e664613_8k-arct.htm 5.07 0001193805-25-000820 001-38942 251030606 34 212742 1 1
2025-05-12 10-Q 10-Q 0000950170-25-069210 001-38942 25934929 34 6053718 1 1
2025-05-12 8-K e664482_8k-arct.htm 2.02,9.01 0001193805-25-000630 001-38942 25934735 34 294833 1 1
2025-05-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001140361-25-018349 005-91046 25934113 34 11721
2025-04-25 DEF 14A e664405_def14a-arct.htm 0001193805-25-000561 001-38942 25875213 34 723714
2025-04-25 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-25-006367 005-91046 25869783 34 11902
2025-04-23 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-001467 005-91046 25863196 34 11126
2025-03-06 10-K 10-K 0000950170-25-034787 001-38942 25715856 34 18088223 1 1
2025-03-06 8-K e664243_8k-arct.htm 2.02,9.01 0001193805-25-000275 001-38942 25715122 34 321213 1 1
2025-02-05 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000093751-25-000091 005-91046 25590935 34 8090
2024-12-18 4 xslF345X05/e664086_4-kurata.xml 0001193805-24-001493 5816
2024-12-18 4 xslF345X05/e664085_4-payne.xml 0001193805-24-001492 5820
2024-12-18 4 xslF345X05/e664084_4-chivukula.xml 0001193805-24-001491 5836
2024-12-18 4 xslF345X05/e664083_4-sassine.xml 0001193805-24-001490 5789
2024-11-08 SC 13G SC 13G 0001140361-24-045812 005-91046 241440120 34 69156
2024-11-07 10-Q 10-Q 0000950170-24-123469 001-38942 241436852 34 5908548 1 1
2024-11-07 8-K e663993_8k-arct.htm 2.02,9.01 0001193805-24-001318 001-38942 241436238 34 286669 1 1
2024-11-05 SC 13G arct1027246sc13g.htm 0001214659-24-018425 005-91046 241425444 34 62985
2024-10-16 4 xslF345X05/e663956_4-chivukula.xml 0001193805-24-001248 5429
2024-10-15 144 xsl144X01/primary_doc.xml 0001971857-24-000670 001-38942 241372163 33 4437
2024-08-13 8-K e663829_8k-arct.htm 7.01,9.01 0001193805-24-001023 001-38942 241198811 34 5577800 1 1
2024-08-05 10-Q 10-Q 0000950170-24-090905 001-38942 241175638 34 5918354 1 1
2024-08-05 8-K e663815_8k-arct.htm 2.02,9.01 0001193805-24-000990 001-38942 241174821 34 305334 1 1
2024-07-17 S-8 e663719_s8-arct.htm 0001193805-24-000937 333-280860 241123075 33 209335
2024-06-24 8-K e663734_8k-arct.htm 5.02,7.01,9.01 0001193805-24-000842 001-38942 241064346 34 219919 1 1
2024-06-21 4 xslF345X05/e663735_4-jing.xml 0001193805-24-000836 7938
2024-06-21 3 xslF345X02/e663736_3-jing.xml 0001193805-24-000835 3054
2024-06-18 4 xslF345X05/e663730_4-jing.xml 0001193805-24-000829 9855
2024-06-18 4 xslF345X05/e663729_4-holmes.xml 0001193805-24-000828 9845
2024-06-18 4 xslF345X05/e663728_4-markels.xml 0001193805-24-000827 9865
2024-06-18 4 xslF345X05/e663727_4-marquet.xml 0001193805-24-000826 10534
2024-06-18 4 xslF345X05/e663726_4-barlow.xml 0001193805-24-000825 9797
2024-06-18 4 xslF345X05/e663725_4-farrell.xml 0001193805-24-000824 10697
2024-06-18 144 xsl144X01/primary_doc.xml 0001972362-24-000923 001-38942 241053226 33 8069
2024-06-14 8-K e663711_8k-arct.htm 5.02,5.07,9.01 0001193805-24-000806 001-38942 241045342 34 405746 1 1
2024-06-14 4 xslF345X05/e663716_4-sassine.xml 0001193805-24-000801 5385
2024-06-12 144 xsl144X01/primary_doc.xml 0001949846-24-000345 001-38942 241037654 33 4270
2024-06-07 4 xslF345X05/e663692_4-chivukula.xml 0001193805-24-000768 5316
2024-06-05 144 xsl144X01/primary_doc.xml 0001971857-24-000352 001-38942 241022754 33 6572
2024-06-04 4 xslF345X05/e663681_4-chivukula.xml 0001193805-24-000746 5425
2024-06-03 144 xsl144X01/primary_doc.xml 0001971857-24-000335 001-38942 241013006 33 5857
2024-05-08 10-Q 10-Q 0000950170-24-055702 001-38942 24926356 34 5809909 1 1
2024-05-08 8-K e663590_8k-arct.htm 2.02,9.01 0001193805-24-000614 001-38942 24925804 34 304442 1 1
2024-04-29 DEF 14A e663528_def14a-arct.htm 0001193805-24-000574 001-38942 24890603 34 911069
2024-04-05 8-K e663496_8k-arct.htm 4.01,9.01 0001193805-24-000505 001-38942 24827264 34 206136 1 1
2024-04-05 SC 13G/A us03969t1097_040424.txt 0001086364-24-007344 005-91046 24825578 34 13774
2024-03-27 4 xslF345X05/e663461_4-chivukula.xml 0001193805-24-000452 5427
2024-03-21 4 xslF345X05/e619136_4-chivukula.xml 0001193805-24-000426 5424
2024-03-19 144 xsl144X01/primary_doc.xml 0002002698-24-000009 001-38942 24764080 33 4434
2024-03-19 8-K e619378_8k-arct.htm 7.01,9.01 0001193805-24-000392 001-38942 24760979 34 240267 1 1
2024-03-14 10-K 10-K 0000950170-24-031156 001-38942 24748092 34 18608954 1 1
2024-03-14 8-K/A e619365_8ka-arct.htm 2.02,9.01 0001193805-24-000364 001-38942 24748083 34 206165 1 1
2024-03-07 8-K e619328_8k-arct.htm 2.02,9.01 0001193805-24-000335 001-38942 24730055 34 303172 1 1
2024-02-23 8-K e619292_8k-arct.htm 5.02,9.01 0001193805-24-000264 001-38942 24671126 34 193671 1 1
2024-02-13 SC 13G/A SCHEDULE 13G/A 0001104659-24-020320 005-91046 24627479 34 13126
2024-02-12 SC 13G/A SC 13G/A 0001140361-24-007096 005-91046 24621778 34 62763
2024-02-05 SC 13G/A AMENDMENT NO. 2 0001214659-24-001839 005-91046 24593846 34 64322
2024-01-29 SC 13G/A SC 13G/A 0001104659-24-007711 005-91046 24573555 34 51871
2024-01-25 SC 13G/A us03969t1097_012524.txt 0001086364-24-003240 005-91046 24561017 34 13778
2024-01-25 SC 13G/A ArcturusTherapeu.txt 0000093751-24-000198 005-91046 24558599 34 8560
2024-01-17 SC 13G/A arct1567-form.htm 0001623632-24-000025 005-91046 24538026 34 433059
2023-12-19 4 xslF345X05/e619137_4-sassine.xml 0001193805-23-001630 5789
2023-12-19 4 xslF345X05/e619136_4-chivukula.xml 0001193805-23-001629 5839
2023-12-19 4 xslF345X05/e619135_4-kurata.xml 0001193805-23-001628 5816
2023-12-19 4 xslF345X05/e619134_4-kummerfeld.xml 0001193805-23-001627 5912
2023-12-19 4 xslF345X05/e619133_4-payne.xml 0001193805-23-001626 5820
2023-11-14 10-Q 10-Q 0000950170-23-063778 001-38942 231407140 34 7071222 1 1
2023-11-14 8-K e619057_8k-arct.htm 2.02,9.01 0001193805-23-001493 001-38942 231406214 34 316869 1 1
2023-11-03 4 xslF345X05/e619041_4-chivukula.xml 0001193805-23-001470 5345
2023-10-10 SC 13G/A Arcturus_Thera_Hold_Inc.txt 0000093751-23-000683 005-91046 231316636 34 8474
2023-10-04 4 xslF345X05/e618979_4-chivukula.xml 0001193805-23-001361 5344
2023-10-02 144 xsl144X01/primary_doc.xml 0001971857-23-000719 001-38942 231299952 33 7195
2023-09-26 8-K e618944_8k-arct.htm 1.01,8.01,9.01 0001193805-23-001328 001-38942 231280538 34 215110 1 1
2023-09-05 4 xslF345X05/e618918_4-chivukula.xml 0001193805-23-001249 5346
2023-09-01 144 xsl144X01/primary_doc.xml 0001971857-23-000605 001-38942 231230939 33 7196
2023-08-17 4 xslF345X05/e618886_4-sassine.xml 0001193805-23-001195 5024
2023-08-14 8-K e618874_8k-arct.htm 1.01,8.01,9.01 0001193805-23-001174 001-38942 231169880 34 211356 1 1
2023-08-07 10-Q 10-Q 0000950170-23-039149 001-38942 231148352 34 7900540 1 1
2023-08-07 8-K e618839_8k-arct.htm 2.02,8.01,9.01 0001193805-23-001112 001-38942 231147932 34 475700 1 1
2023-08-07 424B5 e618843_424b5-arct.htm 0001193805-23-001110 333-269003 231147901 33 13077
2023-08-03 4 xslF345X05/e618822_4-chivukula.xml 0001193805-23-001075 5341
2023-08-03 4 xslF345X05/e618812_4-markels.xml 0001193805-23-001074 8542
2023-08-03 4 xslF345X05/e618811_4-farrell.xml 0001193805-23-001073 8673
2023-08-03 4 xslF345X05/e618810_4-jing.xml 0001193805-23-001072 8532
2023-08-03 4 xslF345X05/e618809_4-holmes.xml 0001193805-23-001071 8521
2023-08-03 4 xslF345X05/e618808_4-barlow.xml 0001193805-23-001070 8473
2023-08-03 4 xslF345X05/e618807_4-marquet.xml 0001193805-23-001069 8506
2023-08-01 144 xsl144X01/primary_doc.xml 0001971857-23-000458 001-38942 231130217 33 8615
2023-07-18 4 xslF345X05/e618783_4-chivukula.xml 0001193805-23-001003 5342
2023-07-18 4 xslF345X05/e618788_4-kummerfeld.xml 0001193805-23-001002 16399
2023-07-14 144 xsl144X01/primary_doc.xml 0001950047-23-002344 001-38942 231089691 33 5370
2023-07-14 144 xsl144X01/primary_doc.xml 0001971857-23-000390 001-38942 231088980 33 8620
2023-07-14 8-K e618777_8k-arct.htm 7.01 0001193805-23-000984 001-38942 231088046 34 198862 1 1
2023-07-07 4 xslF345X04/e618766_4-chivukula.xml 0001193805-23-000955 5339
2023-06-30 8-K e618740_8k-arct.htm 7.01,9.01 0001193805-23-000929 001-38942 231059599 34 218402 1 1
2023-06-16 8-K e618703_8k-arct.htm 5.07 0001193805-23-000861 001-38942 231021727 34 206562 1 1
2023-06-05 4 xslF345X04/e618686_4-chivukula.xml 0001193805-23-000824 5338
2023-05-12 4 xslF345X04/e618625_4-chivukula.xml 0001193805-23-000719 7409
2023-05-11 144 xsl144X01/primary_doc.xml 0001971857-23-000095 001-38942 23911974 33 7195
2023-05-10 144 xsl144X01/primary_doc.xml 0001971857-23-000089 001-38942 23908465 33 6512
2023-05-09 10-Q 10-Q 0000950170-23-019773 001-38942 23902764 34 7977395 1 1
2023-05-09 8-K e618600_8k-arct.htm 2.02,9.01 0001193805-23-000686 001-38942 23902099 34 275477 1 1
2023-05-03 4 xslF345X04/e618570_4-chivukula.xml 0001193805-23-000656 5333
2023-05-01 DEF 14A e618536_def14a-arct.htm 0001193805-23-000633 001-38942 23874247 34 601648
2023-04-28 8-K FORM 8-K 7.01,9.01 0001193805-23-000619 001-38942 23859810 34 219078 1 1
2023-04-21 8-K e618524_8k-arct.htm 1.01,2.03,9.01 0001193805-23-000595 001-38942 23837334 34 197444 1 1
2023-04-19 4 xslF345X04/e618515_4-kummerfeld.xml 0001193805-23-000578 16483
2023-04-17 144 xsl144X01/primary_doc.xml 0001950047-23-000155 001-38942 23824930 33 4697
2023-04-11 8-K e618488_8k-arct.htm 7.01,9.01 0001193805-23-000532 001-38942 23812464 34 200233 1 1
2023-04-05 4 xslF345X04/e618445_4-chivukula.xml 0001193805-23-000516 5335
2023-03-29 10-K 10-K 0000950170-23-010380 001-38942 23771164 34 17477426 1 1
2023-03-28 8-K e618402_8k-arct.htm 2.02,9.01 0001193805-23-000401 001-38942 23769628 34 299382 1 1
2023-03-17 8-K e618370_8k-arct.htm 1.02 0001193805-23-000356 001-38942 23742773 34 194573 1 1
2023-03-08 4 xslF345X03/e618338_4-chivukula.xml 0001193805-23-000295 5303
2023-02-10 SC 13G/A SC 13G/A 0001104659-23-018109 005-91046 23609294 34 45006
2023-02-10 SC 13G/A SC 13G/A 0001140361-23-005791 005-91046 23609168 34 68700
2023-02-09 SC 13G SCHEDULE 13G 0001104659-23-015345 005-91046 23602456 34 13016
2023-02-08 SC 13G/A Arcturus_Thera_Hold_Inc.txt 0000093751-23-000343 005-91046 23597405 34 10371
2023-02-03 SC 13G/A AMENDMENT NO. 1 0001214659-23-001559 005-91046 23583646 34 63246
2023-02-01 SC 13G/A form817.htm 0001623632-23-000210 005-91046 23575092 34 212961
2023-01-31 SC 13G/A us03969t1097_013123.txt 0001306550-23-005189 005-91046 23571845 34 13441
2022-12-30 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2022-12-30 17:00:00 9999999995-23-000017 333-269003 23500004 33 1749
2022-12-30 CORRESP filename1.htm 0001193805-22-001808 7323
2022-12-29 UPLOAD filename1.pdf 0000000000-22-014003 40282
2022-12-27 DEL AM e618160_delam-arct.htm 0001193805-22-001791 333-269003 221491123 33 6425
2022-12-23 S-3 e618047_s3-at.htm 0001193805-22-001786 333-269003 221485990 33 1114683
2022-12-19 4 xslF345X03/e618133_4-marquet.xml 0001193805-22-001748 4679
2022-12-16 4 xslF345X03/e618136_4-kummerfeld.xml 0001193805-22-001746 5872
2022-12-13 8-K e618121_8k-arct.htm 5.02,7.01,9.01 0001193805-22-001719 001-38942 221459874 34 214111 1 1
2022-12-13 4 xslF345X03/e618117_4-markels.xml 0001193805-22-001718 7933
2022-12-13 3 xslF345X02/e618110_3-markels.xml 0001193805-22-001717 3011
2022-12-13 4 xslF345X03/e618109_4-sassine.xml 0001193805-22-001716 5765
2022-12-13 4 xslF345X03/e618108_4-payne.xml 0001193805-22-001715 5793
2022-12-13 4 xslF345X03/e618107_4-chivukula.xml 0001193805-22-001714 5812
2022-12-13 4 xslF345X03/e618106_4-kurata.xml 0001193805-22-001713 5792
2022-12-13 8-K e618105_8k-arct.htm 7.01,9.01 0001193805-22-001712 001-38942 221458593 34 199309 1 1
2022-11-28 4 xslF345X03/e618061_4-payne.xml 0001193805-22-001614 4792
2022-11-09 10-Q 10-Q 0000950170-22-023969 001-38942 221373454 34 10866158 1 1
2022-11-09 8-K e618005_8k-arct.htm 2.02,9.01 0001193805-22-001504 001-38942 221372539 34 282754 1 1
2022-11-04 8-K FORM 8-K 1.01,1.02,9.01 0001193805-22-001480 001-38942 221362962 34 324406 1 1
2022-11-02 8-K e617985_8k-arct.htm 1.01,9.01 0001193805-22-001470 001-38942 221351824 34 225208 1 1
2022-09-01 8-K e621904_8k-arct.htm 1.01,9.01 0001193805-22-001230 001-38942 221221687 34 214317 1 1
2022-08-17 4 xslF345X03/e621887_4-sassine.xml 0001193805-22-001207 4993
2022-08-09 10-Q 10-Q 0000950170-22-016043 001-38942 221148323 34 7270513 1 1
2022-08-09 8-K e621864_8k-arct.htm 2.02,9.01 0001193805-22-001152 001-38942 221148079 34 285749 1 1
2022-06-30 S-8 e621786_s8-arct.htm 0001193805-22-001036 333-265925 221058077 33 216379
2022-06-27 4 xslF345X03/e621785_4-farrell.xml 0001193805-22-001024 5534
2022-06-27 4 xslF345X03/e621784_4-marquet.xml 0001193805-22-001023 5368
2022-06-27 4 xslF345X03/e621783_4-jing.xml 0001193805-22-001022 5381
2022-06-27 4 xslF345X03/e621782_4-barlow.xml 0001193805-22-001021 5334
2022-06-27 4 xslF345X03/e621781_4-holmes.xml 0001193805-22-001020 5383
2022-06-24 8-K e621778_8k-arct.htm 1.01,5.07,9.01 0001193805-22-001014 001-38942 221040978 34 420192 1 1
2022-06-23 4 xslF345X03/e621776_4-kummerfeld.xml 0001193805-22-001003 6052
2022-06-23 4 xslF345X03/e621773_4-chivukula.xml 0001193805-22-001002 5989
2022-06-23 4 xslF345X03/e621772_4-payne.xml 0001193805-22-001001 5973
2022-06-23 4 xslF345X03/e621771_4-sassine.xml 0001193805-22-001000 5942
2022-06-23 4 xslF345X03/e621770_4-kurata.xml 0001193805-22-000999 5954
2022-05-12 DEFR14A e621618_defr14a-arct.htm 0001193805-22-000778 001-38942 22918786 34 762508
2022-05-09 10-Q 10-Q 0000950170-22-008524 001-38942 22905538 34 6422427 1 1
2022-05-09 8-K e621634_8k-arct.htm 2.02,9.01 0001193805-22-000752 001-38942 22905300 34 302781 1 1
2022-05-02 DEF 14A e621607_def14a-arct.htm 0001193805-22-000731 001-38942 22883307 34 760806
2022-04-20 8-K e621578_8k-arct.htm 1.01,1.02,8.01,9.01 0001193805-22-000672 001-38942 22839060 34 233206 1 1
2022-04-11 SC 13G/A Arcturus_Therapeutics.txt 0000093751-22-000487 005-91046 22819296 34 10404
2022-03-01 10-K 10-K 0001564590-22-007832 001-38942 22693445 34 22173701 1 1
2022-02-28 8-K e621394_8k-arct.htm 2.02,9.01 0001193805-22-000402 001-38942 22689760 34 287286 1 1
2022-02-17 8-K e621367_8k-arct.htm 8.01,9.01 0001193805-22-000358 001-38942 22645670 34 8820141 1 1
2022-02-15 SC 13G e621353_sc13g-vpi.htm 0001193805-22-000325 35281
2022-02-14 SC 13G/A arct13gadec21.txt 0000080255-22-002218 005-91046 34 7074
2022-02-14 SC 13G form37.htm 0001623632-22-000216 005-91046 22628540 34 278185
2022-02-14 SC 13G SC13G 0001140361-22-005022 005-91046 22624439 34 63433
2022-02-11 8-K e621318_8k-arct.htm 5.02 0001193805-22-000265 001-38942 22622363 34 192400 1 1
2022-02-11 SC 13G ARCTURUS_THERAPEUTICS_.txt 0000093751-22-000236 005-91046 22617167 34 10360
2022-02-09 SC 13G/A SC 13G/A 0001104659-22-016106 005-91046 22605761 34 41095
2022-02-04 SC 13G arct21224sc13g.htm 0001214659-22-001836 005-91046 22590810 34 63130
2022-02-03 SC 13G/A us03969t1097_020322.txt 0000834237-22-006390 005-91046 22589150 34 13465
2022-01-11 8-K e621207_8k-arct.htm 7.01 0001193805-22-000036 001-38942 22522722 34 196994 1 1
2022-01-06 4 xslF345X03/e621194_4-chivukula.xml 0001193805-22-000015 4756
2021-12-20 4 xslF345X03/e621144_4-chivukula.xml 0001193805-21-001784 4759
2021-12-13 8-K e621155_8k-at.htm 5.02,5.05,7.01,9.01 0001193805-21-001738 001-38942 211488884 34 345733 1 1
2021-12-10 4 xslF345X03/e621144_4-chivukula.xml 0001193805-21-001726 4757
2021-12-09 4 xslF345X03/e621146_4-jing.xml 0001193805-21-001718 7883
2021-12-09 3 xslF345X02/e621145_3-jing.xml 0001193805-21-001717 2961
2021-11-16 8-K e621084_8k-at.htm 8.01,9.01 0001193805-21-001584 001-38942 211416260 34 7854563 1 1
2021-11-09 SC 13G/A SCHEDULE 13G/A 0001104659-21-136120 005-91046 211390929 34 52354
2021-11-09 10-Q ARCT Q3 20210930 0001564590-21-055372 001-38942 211389389 34 8103076 1 1
2021-11-08 8-K e621064_8k-at.htm 2.02,9.01 0001193805-21-001541 001-38942 211388224 34 293082 1 1
2021-11-03 4 xslF345X03/e621049_4-chivukula.xml 0001193805-21-001522 5312
2021-11-01 8-K e621046_8k-at.htm 1.01,9.01 0001193805-21-001517 001-38942 211367634 34 194211 1 1
2021-10-26 SC 13D/A SC 13D/A 0001193125-21-308036 005-91046 211349171 34 43425
2021-10-20 S-8 e621018_s8-arct.htm 0001193805-21-001468 333-260391 211334957 33 214700
2021-10-05 8-K e620993_8k-at.htm 1.01,2.03 0001193805-21-001417 001-38942 211307538 34 195111 1 1
2021-10-04 4 xslF345X03/e620990_4-chivukula.xml 0001193805-21-001408 5311
2021-09-02 4 xslF345X03/e620921_4-chivukula.xml 0001193805-21-001272 5313
2021-08-26 8-K e620900_8k-arct.htm 1.02,5.02 0001193805-21-001224 001-38942 211212528 34 195162 1 1
2021-08-12 4 FORM 4 SUBMISSION 0001209191-21-051182 7269
2021-08-12 SC 13D/A SC 13D/A 0001193125-21-244861 005-91046 211168626 34 43345
2021-08-10 NT 10-Q e620856_nt10q-arct.htm 0001193805-21-001143 001-38942 211158174 34 18266
2021-08-10 10-Q ARCT Q2 20210630 0001564590-21-042750 001-38942 211157673 34 7650654 1 1
2021-08-09 8-K e620853_8k-arct.htm 2.02,7.01,9.01 0001193805-21-001134 001-38942 211156370 34 9276519 1 1
2021-08-05 4 xslF345X03/e620845_4-chivukula.xml 0001193805-21-001112 5310
2021-08-04 8-K e620837_8k-at.htm 1.01 0001193805-21-001100 001-38942 211144207 34 198909 1 1
2021-06-22 4 xslF345X03/e620749_4-parschauer.xml 0001193805-21-000929 5358
2021-06-22 4 xslF345X03/e620748_4-marquet.xml 0001193805-21-000928 5365
2021-06-22 4 xslF345X03/e620747_4-holmes.xml 0001193805-21-000927 5380
2021-06-22 4 xslF345X03/e620746_4-barlow.xml 0001193805-21-000926 5331
2021-06-22 4 xslF345X03/e620745_4-farrell.xml 0001193805-21-000925 5531
2021-06-22 8-K e620743_8k-at.htm 5.07 0001193805-21-000923 001-38942 211035708 34 203791 1 1
2021-05-10 10-Q ARCT 10-Q 20210331 0001564590-21-026113 001-38942 21908114 34 5139982 1 1
2021-05-10 8-K e620580_8k-arct.htm 2.02,7.01,9.01 0001193805-21-000630 001-38942 21907527 34 8298770 1 1
2021-04-30 DEF 14A e620530_def14a-arct.htm 0001193805-21-000583 001-38942 21877654 34 612316
2021-04-26 8-K e620514_8k-arct.htm 5.02,9.01 0001193805-21-000538 001-38942 21854943 34 264557 1 1
2021-04-05 4 xslF345X03/e620448_4-chivukula.xml 0001193805-21-000455 5308
2021-03-03 4 xslF345X03/e620351_4-chivukula.xml 0001193805-21-000323 5308
2021-03-01 8-K e620337_8k-arct.htm 2.02,7.01,9.01 0001193805-21-000289 001-38942 21698049 34 8381304 1 1
2021-03-01 10-K ARCT 10-K 20201231 0001564590-21-009872 001-38942 21698006 34 11123812 1 1
2021-02-22 8-K e620313_8k-arct.htm 3.02,8.01,9.01 0001193805-21-000256 001-38942 21661148 34 209581 1 1
2021-02-16 SC 13G/A SC 13G/A 0001104659-21-024172 005-91046 21639382 34 44791
2021-02-16 SC 13G/A sched13g.htm 0000929638-21-000368 005-91046 21636790 34 85631
2021-02-16 SC 13G arct13gdec20.txt 0000080255-21-001330 005-91046 34 6876
2021-02-12 SC 13G/A SC 13G/A 0001104659-21-021915 005-91046 21627341 34 210962
2021-02-10 3 xslF345X02/e620263_3-arct.xml 0001193805-21-000156 001-40034 21609391 34 4298
2021-02-03 4 xslF345X03/e620251_4-chivukula.xml 0001193805-21-000124 5311
2021-02-03 8-K FORM 8-K- 2.03 0001193805-21-000122 001-38942 21585340 34 197363 1 1
2021-02-02 SC 13G us03969t1097_020221.txt 0000834237-21-007117 005-91046 21580871 34 13369
2021-01-08 SC 13G form.htm 0001623632-21-000003 005-91046 21516917 34 438006
2021-01-05 4 xslF345X03/e620192_4-chivukula.xml 0001193805-21-000014 5310
2020-12-22 4 xslF345X03/e620165_4-kummerfeld.xml 0001193805-20-001611 5468
2020-12-22 4 xslF345X03/e620164_4-chivukula.xml 0001193805-20-001610 5417
2020-12-22 4 xslF345X03/e620163_4-payne.xml 0001193805-20-001609 5389
2020-12-22 4 xslF345X03/e620162_4-sassine.xml 0001193805-20-001608 6188
2020-12-22 4 xslF345X03/e620161_4-hughes.xml 0001193805-20-001607 5375
2020-12-22 4 xslF345X03/e620160_4-kurata.xml 0001193805-20-001606 5379
2020-12-10 4 FORM 4 SUBMISSION 0001209191-20-062733 7303
2020-12-10 SC 13D/A SC 13D/A 0001193125-20-314963 005-91046 201381196 34 40753
2020-12-08 424B5 e620129_424b5-at.htm 0001193805-20-001522 333-251175 201376195 33 440877
2020-12-08 8-K e620125_8k-at.htm 1.01,7.01,9.01 0001193805-20-001508 001-38942 201374488 34 9165338 1 1
2020-12-07 424B5 e620118_424b5-at.htm 0001193805-20-001505 333-251175 201373529 33 438862
2020-12-07 S-3ASR e620120_s3asr-at.htm 0001193805-20-001500 333-251175 201372896 33 700381
2020-12-07 8-K e620119_8k-at.htm 1.01,9.01 0001193805-20-001498 001-38942 201371242 34 225838 1 1
2020-12-03 4 xslF345X03/e620114_4-chivukula.xml 0001193805-20-001491 5317
2020-11-25 8-K e620104_8k-at.htm 5.03,9.01 0001193805-20-001470 001-38942 201351353 34 203100 1 1
2020-11-13 8-K e620078_8k-at.htm 5.07,9.01 0001193805-20-001417 001-38942 201308606 34 195830 1 1
2020-11-09 10-Q Q3 2020 10-Q 0001564590-20-052527 001-38942 201297990 34 5692745 1
2020-11-09 8-K e620071_8k-at.htm 2.02,9.01 0001193805-20-001406 001-38942 201297703 34 273758 1 1
2020-11-03 4 FORM 4 SUBMISSION 0000899243-20-030320 5455
2020-10-15 8-K e6120001_8k-at.htm 8.01,9.01 0001193805-20-001274 001-38942 201240282 34 195028 1 1
2020-10-13 DEF 14A e619993_def14a-arct.htm 0001193805-20-001272 001-38942 201236425 34 152937
2020-10-09 SC 13G/A SC 13G/A 0001104659-20-113789 005-91046 201232771 34 46633
2020-10-02 4 FORM 4 SUBMISSION 0000899243-20-026884 5454
2020-10-02 PRE 14A e619969_pre14a-arct.htm 0001193805-20-001230 001-38942 201220274 34 137045
2020-10-02 8-K e619976_8k-at.htm 8.01,9.01 0001193805-20-001229 001-38942 201220175 34 195781 1 1
2020-09-11 SC 13G SC 13G 0001104659-20-104394 005-91046 201170918 34 165551
2020-09-04 4 FORM 4 SUBMISSION 0000899243-20-024363 5494
2020-08-18 8-K e619881_8k-at.htm 1.01,7.01,9.01 0001193805-20-001052 001-38942 201113582 34 218240 1 1
2020-08-12 4 xslF345X03/e619870_4-kurata.xml 0001193805-20-001022 5349
2020-08-12 3 xslF345X02/e619869_3-kurata.xml 0001193805-20-001021 11353
2020-08-10 10-Q 10-Q 20200630 0001564590-20-038980 001-38942 201090130 34 5023365 1
2020-08-10 8-K e619846_8k-at.htm 2.02,9.01 0001193805-20-000987 001-38942 201089672 34 74725
2020-08-05 S-8 e619825_s8-at.htm 0001193805-20-000940 333-240397 201074618 33 205833
2020-08-05 S-8 e619826_s8-at.htm 0001193805-20-000939 333-240392 201074567 33 175945
2020-07-30 424B5 e619812_424b5-at.htm 0001193805-20-000907 333-238139 201059008 33 413365
2020-07-29 8-K e619811_8k-at.htm 1.01,9.01 0001193805-20-000902 001-38942 201055606 34 334425
2020-07-28 424B5 e619809_424b5-at.htm 0001193805-20-000900 333-238139 201054052 33 410661
2020-07-24 8-K e619804_8k-at.htm 8.01,9.01 0001193805-20-000886 001-38942 201044975 34 30711
2020-06-26 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2020-06-26 16:00:00 9999999995-20-001665 333-235475 201017185 33 1750
2020-06-24 4 xslF345X03/e619725_4-parschauer.xml 0001193805-20-000746 5281
2020-06-24 4 xslF345X03/e619724_4-marquet.xml 0001193805-20-000745 5288
2020-06-24 4 xslF345X03/e619723_4-holmes.xml 0001193805-20-000744 5303
2020-06-24 4 xslF345X03/e619722_4-barlow.xml 0001193805-20-000743 5254
2020-06-24 4 xslF345X03/e619721_4-farrell.xml 0001193805-20-000742 5454
2020-06-19 CORRESP filename1.htm 0001193805-20-000721 7332
2020-06-18 8-K e619707_8k-at.htm 7.01,9.01 0001193805-20-000704 001-38942 20971903 34 2460354
2020-06-12 4 FORM 4 SUBMISSION 0000899243-20-016410 4639
2020-06-10 4 FORM 4 SUBMISSION 0000899243-20-016050 4733
2020-06-10 4 FORM 4 SUBMISSION 0000899243-20-016049 4561
2020-06-09 8-K 8-K 5.07 0001193125-20-164097 001-38942 20950828 34 32902
2020-05-22 SC 13D/A SC 13D/A 0001193125-20-150308 005-91046 20907120 34 57766
2020-05-22 S-3/A e619657_s3a-at.htm 0001193805-20-000627 333-235475 20907074 33 165263
2020-05-22 4 FORM 4 SUBMISSION 0001209191-20-031641 6931
2020-05-21 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2020-05-21 16:00:00 9999999995-20-001236 333-238139 20903529 33 1749
2020-05-21 8-K e619655_8k-at.htm 3.02,7.01,9.01 0001193805-20-000622 001-38942 20902336 34 32061
2020-05-18 CORRESP filename1.htm 0001193805-20-000600 7441
2020-05-15 UPLOAD filename1.pdf 0000000000-20-004351 40206
2020-05-08 S-3 e619613_s3-at.htm 0001193805-20-000569 333-238139 20861820 33 815086
2020-05-08 10-Q 10-Q Q1 2020 0001564590-20-023633 001-38942 20861463 34 4103543 1
2020-05-07 8-K e619610_8k-at.htm 2.02,9.01 0001193805-20-000565 001-38942 20856364 34 69677
2020-04-29 DEF 14A e619589_def14a-arct.htm 0001193805-20-000535 001-38942 20831072 34 678427
2020-04-27 SC 13G sched13g.htm 0000929638-20-000538 005-91046 20819980 34 90563
2020-04-21 8-K 8-K 8.01 0001564590-20-017549 001-38942 20803889 34 33968
2020-04-17 424B5 e619560_424b5-at.htm 0001193805-20-000494 333-232281 20799680 33 348572
2020-04-17 8-K 8-K 1.01,1.02,8.01,9.01 0001564590-20-017147 001-38942 20797611 34 378298
2020-04-16 S-3MEF e619559_s3mef-at.htm 0001193805-20-000491 333-237703 20795110 33 73050
2020-04-15 424B5 e619556_424b5-at.htm 0001193805-20-000486 333-232281 20793844 33 345903
2020-03-27 8-K e619507_8k-at.htm 1.01,9.01 0001193805-20-000412 001-38942 20752944 34 271811
2020-03-27 424B5 e619508_424b5-at.htm 0001193805-20-000411 333-232281 20752938 33 313877
2020-03-16 10-K ARCT 10-K 20191231 0001564590-20-011037 001-38942 20715874 34 8528884 1
2020-03-11 8-K e619458_8k-at.htm 2.02,9.01 0001193805-20-000335 001-38942 20705280 34 68397
2020-03-04 8-K e619429_8k-at.htm 1.01 0001193805-20-000295 001-38942 20685799 34 34480
2020-02-24 SEC STAFF LETTER filename1.pdf 9999999997-20-000993 226536
2020-02-20 4 FORM 4 SUBMISSION 0000899243-20-005389 5461
2020-02-20 4 FORM 4 SUBMISSION 0000899243-20-005387 5503
2020-02-20 4 FORM 4 SUBMISSION 0000899243-20-005386 5430
2020-02-20 4 FORM 4 SUBMISSION 0000899243-20-005383 5421
2020-02-20 3 FORM 3 SUBMISSION 0000899243-20-005382 2985
2020-02-20 4 FORM 4 SUBMISSION 0000899243-20-005379 5454
2020-02-03 SEC STAFF LETTER filename1.pdf 9999999997-20-000424 230871
2020-01-10 8-K e619284_8k-at.htm 7.01,9.01 0001193805-20-000030 001-38942 20521396 34 5176122
2019-12-16 UPLOAD filename1.pdf 0000000000-19-016451 46088
2019-12-12 S-3 S-3 0001193125-19-312823 333-235475 191282451 33 219048
2019-12-09 4 FORM 4 SUBMISSION 0000899243-19-028803 5072
2019-12-05 4 FORM 4 SUBMISSION 0000899243-19-028631 4568
2019-11-08 10-Q 10-Q 0001564590-19-042017 001-38942 191202142 34 5380893 1
2019-11-07 8-K 8-K 2.02,9.01 0001193125-19-287407 001-38942 191201110 34 82510
2019-11-07 8-K 8-K 7.01,9.01 0001193125-19-287260 001-38942 191200168 34 10324236
2019-10-31 8-K 8-K 1.01,5.07 0001193125-19-280541 001-38942 191184215 34 40177
2019-10-29 4 FORM 4 SUBMISSION 0000899243-19-026165 9614
2019-10-29 4 FORM 4 SUBMISSION 0000899243-19-026159 7592
2019-10-29 4 FORM 4 SUBMISSION 0000899243-19-026123 7618
2019-10-29 4 FORM 4 SUBMISSION 0000899243-19-026116 5302
2019-10-29 4 FORM 4 SUBMISSION 0000899243-19-026109 5468
2019-10-01 DEF 14A DEF 14A 0001193125-19-259220 001-38942 191127532 34 1230923
2019-09-27 8-K 8-K 1.01,7.01,9.01 0001193125-19-257389 001-38942 191122378 34 251105
2019-09-27 424B5 424B5 0001193125-19-257362 333-232281 191122264 33 368539
2019-09-24 3 FORM 3 SUBMISSION 0000899243-19-024193 7352
2019-09-23 8-K 8-K 5.02,8.01,9.01 0001193125-19-252227 001-38942 191108394 34 33444
2019-09-17 4 FORM 4 SUBMISSION 0000899243-19-023769 8973
2019-09-16 8-K 8-K 8.01 0001193125-19-245891 001-38942 191095195 34 18195
2019-09-12 4 FORM 4 SUBMISSION 0000899243-19-023531 8972
2019-08-30 4 FORM 4 SUBMISSION 0000899243-19-022619 9313
2019-08-26 4 FORM 4 SUBMISSION 0000899243-19-022418 9616
2019-08-21 4 FORM 4 SUBMISSION 0000899243-19-022258 11806
2019-08-15 8-K FORM 8-K 7.01,9.01 0001193125-19-221871 001-38942 191028532 34 89943
2019-08-14 10-Q 10-Q 0001564590-19-032166 001-38942 191027197 34 6075056 1
2019-08-05 8-K FORM 8-K 1.01,7.01,9.01 0001193125-19-212594 001-38942 19997706 34 205940
2019-08-05 424B5 424B5 0001193125-19-212590 333-232281 19997699 33 367369
2019-08-02 8-K 8-K 1.01,7.01,9.01 0001193125-19-212082 001-38942 19996379 34 269078
2019-08-02 424B5 424B5 0001193125-19-212073 333-232281 19996361 33 365851
2019-08-01 8-K e618580_8k-at.htm 1.01,8.01,9.01 0001193805-19-000694 001-38942 19991828 34 29523

Latest XBRL company facts

One latest value per concept from companyfacts (201 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 28.82M 2026-11-03 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
dei EntityPublicFloat Entity Public Float USD 323.50M 2025-06-30 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 5.77M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 1.25M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 22.16M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 13.49M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 741.45M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 4.04M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 12.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss USD 0 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 100,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap Assets Assets USD 215.32M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap AssetsCurrent Assets, Current USD 189.40M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap AssetsDisposedOfByMethodOtherThanSaleInPeriodOfDispositionGainLossOnDisposition1 Assets Disposed of by Method Other than Sale, in Period of Disposition, Gain (Loss) on Disposition USD 0 2025-07-01 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-275758
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 68,000 2023-01-01 2023-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 184.82M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 186.84M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -45.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 5.53M 2020-09-30 2020 Q3 10-Q 2020-11-09 0001564590-20-052527
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 60.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 28.46M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 28.46M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap CommonStockValue Common Stock, Value, Issued USD 28,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -58.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap ContractualObligation Contractual Obligation USD 3.49M 2023-09-30 2023 Q3 10-Q 2023-11-14 0000950170-23-063778
us-gaap ContractWithCustomerAssetNet Contract with Customer, Asset, after Allowance for Credit Loss USD 1.25M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap ContractWithCustomerLiability Contract with Customer, Liability USD 419,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized USD 803,000 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-16 0001564590-20-011037
us-gaap ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized USD -23.32M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap CumulativeEffectOnRetainedEarningsTax1 Cumulative Effect on Retained Earnings, Tax (Deprecated 2020-01-31) USD -803,000 2019-01-01 2019-03-31 2020 Q1 10-Q 2020-05-08 0001564590-20-023633
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD -11,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD -4,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 7,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap CustomerRefundLiabilityCurrent Customer Refund Liability, Current USD 2.26M 2018-12-31 2019 FY 10-K 2020-03-16 0001564590-20-011037
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 5.17M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap DeferredRentCreditNoncurrent Deferred Rent Credit, Noncurrent USD 534,000 2018-12-31 2019 FY 10-K 2020-03-16 0001564590-20-011037
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 419,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap DeferredRevenueNoncurrent Deferred Revenue, Noncurrent USD 12.60M 2024-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 2.81M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap DeferredTaxAssetsEquityMethodInvestments Deferred Tax Assets, Equity Method Investments USD 2.05M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 148.69M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap DeferredTaxAssetsInventory Deferred Tax Assets, Inventory USD 15.96M 2023-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034787
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2018-12-31 2019 FY 10-K 2020-03-16 0001564590-20-011037
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 38.57M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 30.22M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 15.23M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities USD 689,000 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 143.53M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap DepositLiabilityCurrent Deposit Liability, Current USD 10.00M 2021-06-30 2021 Q2 10-Q 2021-08-10 0001564590-21-042750
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 1.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap Dividends Dividends USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -2.05 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -1.94 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008524
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -2.05 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.361 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure -0.014 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure 0.003 2019-01-01 2019-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007832
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent pure 0.029 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007832
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.019 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.002 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent pure 0.285 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007832
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.019 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsOther Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent pure 0.002 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007832
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 8.50M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 30.10M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap EquityMethodInvestmentAggregateCost Equity Method Investment, Aggregate Cost USD 9.20M 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010380
us-gaap EquityMethodInvestmentOwnershipPercentage Equity Method Investment, Ownership Percentage pure 0.3 2019-12-31 2019 FY 10-K 2020-03-16 0001564590-20-011037
us-gaap EquityMethodInvestments Equity Method Investments USD 515,000 2021-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010380
us-gaap ForeignCurrencyTransactionGainLossBeforeTax Foreign Currency Transaction Gain (Loss), before Tax USD 382,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap ForeignCurrencyTransactionGainLossRealized Foreign Currency Transaction Gain (Loss), Realized USD 2,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD 52,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt USD 33.95M 2023-01-01 2023-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 30.94M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap GoodwillImpairmentLoss Goodwill, Impairment Loss USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -65.78M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -58.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD -69,000 2019-01-01 2019-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007832
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest USD 81.05M 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034787
us-gaap IncomeLossFromEquityMethodInvestments Income (Loss) from Equity Method Investments USD -515,000 2022-01-01 2022-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034787
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 1.41M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 1.53M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD -4.32M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD -1.74M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD -7.83M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -2.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -1.64M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap InterestExpenseLongTermDebt Interest Expense, Long-term Debt USD 900,000 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010380
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 2.13M 2023-01-01 2023-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 25.03M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 7.76M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 4.13M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 4.05M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 4.05M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 3.94M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 3.82M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 1.33M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 3.17M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap Liabilities Liabilities USD 46.59M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 215.32M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap LiabilitiesCurrent Liabilities, Current USD 28.34M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap LongTermDebt Long-term Debt USD 13.30M 2022-09-30 2022 Q3 10-Q 2022-11-09 0000950170-22-023969
us-gaap LongTermDebtCurrent Long-term Debt, Current Maturities USD 60.66M 2022-12-31 2023 FY 10-K 2024-03-14 0000950170-24-031156
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Long-Term Debt, Maturity, Year One USD 10.30M 2022-09-30 2022 Q3 10-Q 2022-11-09 0000950170-22-023969
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Long-Term Debt, Maturity, Year Four USD 6.70M 2020-06-30 2020 Q2 10-Q 2020-08-10 0001564590-20-038980
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Long-Term Debt, Maturity, Year Three USD 6.55M 2020-12-31 2020 FY 10-K 2021-03-01 0001564590-21-009872
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Long-Term Debt, Maturity, Year Two USD 8.63M 2021-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007832
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Long-Term Debt, Maturity, Remainder of Fiscal Year USD 3.00M 2022-09-30 2022 Q3 10-Q 2022-11-09 0000950170-22-023969
us-gaap LongTermDebtNoncurrent Long-term Debt, Excluding Current Maturities USD 15.00M 2025-03-31 2025 Q1 10-Q 2025-05-12 0000950170-25-069210
us-gaap LossContingencyDamagesSoughtValue Loss Contingency, Damages Sought, Value USD 30.00M 2020-01-17 2020 FY 10-K 2021-03-01 0001564590-21-009872
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 307,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -46.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -58.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap OperatingExpenses Operating Expenses USD 86.98M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -63.66M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap OperatingLeaseCost Operating Lease, Cost USD 2.80M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap OperatingLeaseImpairmentLoss Operating Lease, Impairment Loss USD 1.90M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 21.86M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 3.62M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 18.24M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 19.09M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.046 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 560,000 2019-09-30 2019 Q3 10-Q 2019-11-08 0001564590-19-042017
us-gaap OtherAssetsCurrent Other Assets, Current USD 593,000 2020-03-31 2020 Q1 10-Q 2020-05-08 0001564590-20-023633
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD 3,000 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-01 0001564590-21-009872
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 497,000 2023-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034787
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD -502,000 2023-01-01 2023-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD -26,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap PaymentsToAcquireInterestInJointVenture Payments to Acquire Interest in Joint Venture USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010380
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 52,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap PaymentsToAcquireShortTermInvestments Payments to Acquire Short-term Investments USD 6.59M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-01 0001564590-21-009872
us-gaap PrepaidExpenseCurrent Prepaid Expense, Current USD 1.34M 2020-03-31 2020 Q1 10-Q 2020-05-08 0001564590-20-023633
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 11.69M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap ProceedsFromIssuanceOfDebt Proceeds from Issuance of Debt USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-term Debt USD 46.60M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010380
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised USD 15.54M 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-16 0001564590-20-011037
us-gaap ProceedsFromIssuanceOrSaleOfEquity Proceeds from Issuance or Sale of Equity USD 21.40M 2019-07-01 2019-09-30 2019 FY 10-K 2020-03-16 0001564590-20-011037
us-gaap ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments Proceeds from Maturities, Prepayments and Calls of Short-term Investments USD 30.21M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-01 0001564590-21-009872
us-gaap ProceedsFromSaleOfMachineryAndEquipment Proceeds from Sale of Machinery and Equipment USD 52,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 66,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 241,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 18.29M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 4.81M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap RepaymentsOfDebt Repayments of Debt USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 56.04M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap ResearchAndDevelopmentInProcess Research and Development in Process USD 5.00M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010380
us-gaap RestrictedCash Restricted Cash USD 55.00M 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034787
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 2.03M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -572.75M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 23.32M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 2.74M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap SegmentReportingOtherItemAmount SegmentReportingOtherItemAmount USD -5.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 12.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number shares 18,786 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value USD/shares 34.92 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 8.65M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 6.05M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 33.12 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 500,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 1.14M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 2.03M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 3.89 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-14 0001564590-19-032166
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 13.33M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 8.87M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 29.2 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value USD 9.25M 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034787
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number shares 8.08M 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034787
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price USD/shares 32.38 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034787
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value USD 29.30M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 10.72 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 33.9 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 11.37 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap SharePrice Share Price USD/shares 34.92 2023-08-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 168.73M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 1 2019-06-12 2019 FY 10-K 2020-03-16 0001564590-20-011037
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 103,440 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap StockIssuedDuringPeriodValueAcquisitions Stock Issued During Period, Value, Acquisitions USD 5.00M 2021-01-01 2021-12-31 2023 FY 10-K 2024-03-14 0000950170-24-031156
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 11.69M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures USD 15.54M 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-16 0001564590-20-011037
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 50,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap TaxesPayableCurrent Taxes Payable, Current USD 641,000 2023-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034787
us-gaap TreasuryStockCommonShares Treasury Stock, Common, Shares shares 43,000 2018-12-31 2019 FY 10-K 2020-03-16 0001564590-20-011037
us-gaap UnbilledReceivablesCurrent Unbilled Receivables, Current USD 3.61M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 6.94M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007832
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 925,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 300,000 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-01 0001564590-21-009872
us-gaap UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate USD 0 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034787
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 5.50M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088391
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 28.43M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 26.38M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008524
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 28.43M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449901

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →